A Mutated Anti-CA19-9 scFv-Fc for Positron Emission Tomography of Human Pancreatic Cancer Xenografts

Molecular Imaging and Biology

Volumn 16, Issue 5, 2014, Pages 721-729

  Rochefort, Matthew M ^a,b   Girgis, Mark D ^a,b   Knowles, Scott M ^c   Ankeny, Jacob S ^a,b   Salazar, Felix ^c   Wu, Anna M ^c   Tomlinson, James S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Greater Los Angeles ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; CA 19 9; Cancer; Imaging; Pancreas; scFv Fc

Indexed keywords

EID: 84897121934     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0733-4     Document Type: Article

References (31)

1. American Cancer Society (2012) Cancer facts & figures. American Cancer Society, Atlanta
2. Winter JM, Cameron JL, Campbell KA et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1210, discussion 1210-1191
3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29
4. Mancuso A, Calabro F, Sternberg CN (2006) Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 58:231–241
5. Richter A, Niedergethmann M, Sturm JW et al (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27:324–329
6. Wasif N, Ko CY, Farrell J et al (2010) Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol 17:2312–2320
7. Knowles SM, Wu AM (2012) Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 30:3884–3892
8. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287
9. Haglund C, Lindgren J, Roberts PJ, Nordling S (1986) Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer 53:189–195
10. Loy TS, Sharp SC, Andershock CJ, Craig SB (1993) Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases. Am J Clin Pathol 99:726–728
11. Makovitzky J (1986) The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 51:535–544
12. Atkinson BF, Ernst CS, Herlyn M et al (1982) Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 42:4820–4823
13. Chang TH, Steplewski Z, Sears HF, Koprowski H (1981) Detection of monoclonal antibody-defined colorectal carcinoma antigen by solid-phase binding inhibition radioimmunoassay. Hybridoma 1:37–45
14. Girgis MD, Olafsen T, Kenanova V et al (2011) CA19-9 as a potential target for radiolabeled antibody-based positron emission tomography of pancreas cancer. Int J Mol Imaging 2011:834515
15. Girgis MD, Olafsen T, Kenanova V et al (2011) Targeting CEA in pancreas cancer xenografts with a mutated scFv-Fc antibody fragment. EJNMMI Res 1:24
16. Kim JK, Firan M, Radu CG et al (1999) Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 29:2819–2825
17. Shields RL, Namenuk AK, Hong K et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591–6604
18. Girgis MD, Kenanova V, Olafsen T et al (2011) Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res 170:169–178
19. Wu AM, Yazaki PJ (2000) Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med 44:268–283
20. Kenanova V, Olafsen T, Crow DM et al (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65:622–631
21. Galfre G, Milstein C (1981) Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 73:3–46
22. Yu D, Hung MC (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19:6115–6121
23. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51
24. Lepin EJ, Leyton JV, Zhou Y et al (2010) An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 37:1529–1538
25. Defrise M, Kinahan PE, Townsend DW et al (1997) Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 16:145–158
26. Loening AM, Gambhir SS (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2:131–137
27. Wasif N, Bentrem DJ, Farrell JJ et al (2010) Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer 116:3369–3377
28. Picozzi VJ, Abrams RA, Decker PA et al (2011) Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 22:348–354
29. Vaccaro V, Sperduti I, Milella M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 365:768–769, author reply 769
30. Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 93:5512–5516
31. Israel EJ, Wilsker DF, Hayes KC et al (1996) Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89:573–578